Beigene, Ltd., of Beijing, said China's State Medical Insurance Administration has included Vidaza (azacitidine for injection) on its national reimbursement drug list. The nucleoside metabolic inhibitor was approved in China for patients with intermediate-2/high-risk myelodysplastic syndrome, acute myeloid leukemia with 20 percent to 30 percent bone marrow blasts and chronic myelomonocyte leukemia. It is marketed in China under an exclusive license from Celgene Corp., of Summit, N.J.